Background {#Sec1}
==========

Brain metastases (BMs) are common in patients with metastatic melanoma \[[@CR1],[@CR2]\] and are the cause of death in the majority of them \[[@CR2],[@CR3]\]. Whole brain radiotherapy (WBRT) is a common adjuvant treatment following local treatment of BMs with neurosurgery and/or stereotactic irradiation (SRS). However, there is no specific level one evidence to support this approach in melanoma. Proponents believe that WBRT improves palliation by prolonging intracerebral control \[[@CR4]\]. Critics state that WBRT does not increase survival, may cause neurocognitive problems and may not prevent intracerebral progression \[[@CR5],[@CR6]\]. A randomised controlled trial (RCT) is needed to resolve this controversy in melanoma.

The Australia and New Zealand Melanoma Trials Group (ANZMTG) and Trans-Tasman Radiation Oncology Group (TROG) are leading a RCT investigating this question. This trial is known as the **w**hole **b**rain **r**adio**t**herapy in **mel**anoma (WBRTMel) trial. The trial protocol has previously been published \[[@CR7]\]. The primary endpoint is distant intracranial failure on magnetic resonance imaging (MRI) within twelve months of randomisation. The total number of patients required was calculated as being 200, and a feasibility study was completed and reported \[[@CR8]\].

A planned interim analysis performed at twelve months after randomisation of the 100^th^ patient was triggered in December 2013. Clinicians remain blinded to the study results. The interim analysis presented an opportunity to review completeness of the trial data to date and these data are now presented.

Methods {#Sec2}
=======

This is an international, multi-centre, open-label, stratified, 2-arm randomised phase III trial (Figure [1](#Fig1){ref-type="fig"}).Figure 1Trial Schema.

The trial has been approved by the Cancer Institute NSW Clinical Research Ethics Committee \#2007C/11/032 and relevant hospital ethics committees in each participating centre. Written informed consent for participation in the study is obtained from all participants.

The first recruiting centre was opened in December 2008, with the first trial patient randomised in April 2009. The 100^th^ patient was randomised on 3^rd^ December 2012, triggering the first planned interim analysis in December 2013. Data collected until that date was reviewed.

Data were reviewed for quality, and the primary endpoint analysed. Histopathology reports (of primary tumour or metastases) of all 100 patients were independently reviewed. Data recorded on MRI Case Report Forms (CRFs) were compared with corresponding MRI reports. Quality of life (QoL) and neurocognitive function (NCF) data were reviewed for completeness. Radiotherapy (RT) quality review was conducted by TROG Quality Assurance (QA) Team. The first 5 patients from each site randomised to receive whole brain radiotherapy were reviewed for RT QA. Subsequently, patient reviews followed a 1 in 5 random sampling basis from each site, in accordance with the standard TROG QA protocol for all RT trials. A random sample of 10% of the first 100 patients had all critical data points reviewed for accuracy of entry. Safety data for all 130 patients entered onto the trial at the time of the analysis were reviewed.

Whilst trial results remain blinded to clinicians and the Trial Management Committee (TMC), the independent Data Safety Monitoring Committee (DSMC) were presented with the unblinded results (i.e. when reviewing the primary endpoint of the trial, they could ascertain which arm of the trial each patient had been assigned to). The DSMC were also provided with the most recent safety data for all trial patients. The recommendations of the DSMC were presented to the TMC to decide whether to continue the trial.

Results {#Sec3}
=======

Demographics {#Sec4}
------------

Demographic information is presented (Table [1](#Tab1){ref-type="table"}). Briefly, baseline analysis demonstrated even distribution between the treatment groups (50 patients per arm). The 100 patient cohort included 70% males and 30% females, aged between 26 and 83 years. Mean ranges of Australian patients were marginally older than international patients entering the trial (61 years vs 58 years), but balanced between treatment arms (WBRT 61 years vs Observation 59 years). Fifty-nine percent of the first 100 patients presented with a solitary brain metastasis, and the remainder with two (29%) or three metastases (12%). Twenty-seven percent of patients presented at baseline with no evidence of extracranial disease. Demographics reported in this analysis of the first 100 patients are consistent with the results of our feasibility study \[[@CR8]\].Table 1**Patient demographics (First 100 patients)SiteNo. of Patients**Treatment Centre Australian68 International32Gender Male70 Female30Mean Age (years)Mean 61 (Australian) Mean 58 (International) Range: 26 to 83Local treatment of BMs Neurosurgery62 Stereotactic (Radiosurgery (SRS)24 Combination of Neurosurgery and SRS13 None\*1Number of Brain Mets 159 229 312Extracranial Disease Present73 Absent27\*One patient died prior to receiving local treatment to their brain metastases.BM -- brain metastases.

Primary endpoint {#Sec5}
----------------

The primary endpoint was distant intracranial failure on MRI within one year. The primary endpoint was reached in 47 of the first 100 patients: 34 experienced distant intracranial failure only, while in 13 patients it was accompanied by local failure (Figure [2](#Fig2){ref-type="fig"}).Figure 2Number of patients presenting with distant intracranial progression within 365 days of randomisation for the first 100 patients accrued to the ANZMTG 01.07 WBRTMel Trial.

Protocol compliance {#Sec6}
-------------------

MRI schedule data review revealed high protocol compliance; with 81 of the 100 patients having MRI scans performed as per protocol (i.e. every 3 months until distant intracranial progression was reported or until death). Seven patients did not have one or more of their scheduled MRI scans within the first 12 months. One patient had distant failure detected on computed tomography (CT) scan. Twelve patients had further MRI scans, despite confirmation of distant failure. The accuracy of distant intracranial failure reporting was 100%, but stringent quality assurance checks highlighted some minor inaccuracies requiring correction despite their lack of impact on critical end points. Examples of these are outlined below:Only distant failure was reported, when a local failure was present and should also have been documented (n = 1).Information detailed in the MRI report was found to be wrong and the CRF was correct (n = 1).A local failure was reported twice, as the site had reported continued growth of a lesion that had already been recorded as a failure (n = 1).For one instance of failure, only one distant lesion was recorded when two had been identified with the MRI report (n = 1).

Of 50 patients who received WBRT, 32 were reviewed (Table [2](#Tab2){ref-type="table"}). There was only one major variation among the 308 data points reviewed (0.3%). This was due to a patient whose RT delivery time extended beyond 10% of that expected due to a treatment break for concomitant illness. Treatment was subsequently completed.Table 2**Radiotherapy quality assurance data for 32 patients in the interim analysisCategoriesVariables reviewedAcceptableMinor variationMajor variationMissingSchedule**8482110**Dose**110110000**Technique**5856200**Documentation**5656000**Total308304(98.7%)3(1.0%)1(0.3%)0**

Data quality and safety {#Sec7}
-----------------------

Data submitted from all sites were reviewed centrally for completion. Pathology report review confirmed all 100 patients had evidence of AJCC stage IV melanoma and were appropriately entered into the study. Completion of the QoL questionnaires (EORTC QLQC30 and BN20) has been excellent, with a 91% completion rate. For those patients participating in the two monthly NCF assessments (those recruited from Norway were excluded from this component of the trial as English fluency to grade 8 level was a prerequisite), compliance has been high. At baseline 99% of expected assessments were completed. This completion rate decreased overtime (Table [3](#Tab3){ref-type="table"}), however stands at 59% at 12 months. When assessments were not performed at expected time points, valid reasons were noted (e.g. patient too unwell).Table 3**NCF assessment completionTime pointBaselineMonth 2Month 4Month 6Month 8Month 10Month 12Proportion of expected NCF assessments completed (%)**99917868675259For each time point the number of NCF assessments expected to be completed was determined and compared with the number of NCF assessments actually completed. From this the proportion of expected NCF assessments completed were calculated and is displayed in Table [3](#Tab3){ref-type="table"}.

For 10 randomly selected patients, critical data points within the database were reviewed including the Eastern Cooperative Oncology Group (ECOG) Performance Status scores, the NCF and QoL data, leading to verification of 4,440 data fields. From this, a minimal data entry error rate of 0.2% was determined. Safety data review showed that adverse events (AEs) were minimal, with only 47 events of grade 3 or 4 occurring (Table [4](#Tab4){ref-type="table"}). No serious adverse events (SAEs) have been reported to date. None of the protocol specified stopping rules were met.Table 4**Adverse events\*Adverse eventNo. of Grade 3 eventsNo. of Grade 4 events**Anorexia50Aphasia10Cellulitis10Dehydration10Disseminated Intravascular Coagulation01Fatigue152Gait/Walking disturbance20Hemiparesis10Hypokalaemia10Hyponatraemia10Muscle weakness20Nausea10Pain30Peripheral motor neuropathy10Reduced sight10Renal impairment10Seizure20Thromboembolitic event10Vomiting30Weight loss10**Total number of AEs at specified grade =443Total number of AEs =47**\*All AEs have been classified in accordance with CTCAE v 4.0.

Discussion {#Sec8}
==========

The DSMC reviewed the unblinded primary end point interim analysis data and the corresponding safety data for this trial. They stated that the trial is progressing in a manner that is safe for patients, the data collected are of an excellent standard, and no protocol defined stopping rules have been met. Therefore they recommended the trial continue to completion. Based on this recommendation, the TMC, blinded to the primary end point analysis, approved the continuation of the trial. Recruitment to the trial continues with 156 out of 200 patients currently randomised (26^th^ November 2014). The primary end point interim analysis data remains blinded to the WBRTMel Operations Team, the TMC and all investigators, clinicians, site staff, and patients.

For the primary endpoint of distant intracranial progression at 12 months, of the total cohort there were 47 distant intracranial events; 34 occurred in isolation (i.e. only distant failure was identified), whilst 13 were accompanied by local failure. This finding indicates that the trial selection criteria are appropriately identifying a population at high risk of distant intracranial failure, and this risk is similar to that reported in other studies. In a recent retrospective review, Dyer *et al*. \[[@CR9]\] reported 86 of 147 (59%) patients developed distant intracranial progression at a median of 4.3 months. The addition of adjuvant WBRT on multivariate analysis being associated with significantly prolonged intracranial control (HR 2.24, p = 0.005), especially for those with more than one BM.

Protocol compliance and high data quality are essential for ensuring that the trial results are reliable. These results compare favourably with other practice-changing clinical trials \[[@CR10],[@CR11]\]. With regards to the NCF component the WBRTMel trial will provide a more comprehensive data set than previous trials \[[@CR12]\]. The introduction of hippocampal avoidance to the protocol, at centres able to give WBRT in this manner, will also provide an additional perspective on WBRT. At the point of final analysis the NCF of patients who received observation vs WBRT with hippocampal avoidance vs WBRT without hippocampal avoidance will be reviewed. The interim analysis has allowed an opportunity to recheck and clean the data to eradicate errors, both systematic and non-systematic, before the final analysis, due twelve months after the last patient is randomised. Quality is especially important in RT trials, some of which may have foundered because of lack of RT quality control \[[@CR13]\].

Conclusion {#Sec9}
==========

RCTs are fundamental to improving clinical care via the use of evidence--based medicine. Based on a planned interim analysis the WBRTMel trial is safe and with data of high quality. The trial is on track to answer an important controversy in melanoma management and as far as we are aware, remains the first ever reported single tumour type WBRT trial. The full trial continues, with 156 patients of the target 200 randomised to date (26^th^ November 2014).
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